Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's why I chose to exit my position for now
I think data was as expected. Look, cancer patients on TARGETED therapies have a 95% chance of getting CID. Breast and Lung cancer patients in ONTARGET received TARGETED therapies. So, if it worked on 75% of the patients. Which is the group were 95% of the patients get CID, the trial is succesfull... simple.
HOWEVER, I exited my position for the following reason: In my opinion there was not shared any detailed information, because the principal investigator wants to take the data to SABCS (breast cancer symposium), like they did with the phase 2 trial.
I've seen it with other stocks that the principal investigators prefere this. And they decide where data is presented. So in my opinion we can wait for the full data till december 9th (SABCS)
So, unless the POC data for SBS and MVIS shows up, or a a new partnership... it will be a long wait, and shorts will take it down again. That's why I chose to exit, but I will be back in november
I was owning shares. 75% down.
Data was GOOD, as I predicted. Can't blame my own DD
Can blame management. Wtf was that for a shit show. No complete data, horrible press release. Horrible managed
Shorts can say whatever they want, but why is the cost to borrow fee decreasing rapidly?
In 10 trading days from 96% to 9%
Apparently the demand for short shares is decreasing quickly
They will ask for extra shares, but not this week.
That's peanuts. That's a market cap of 87 million dollars, for a drug, unique on his market, in cancer therapy, with the potential of generating billions in revenue...
That's really low
Finally, we arrived to the day we have been waiting for since November 2023. I want to highlight 1 fact:
"Since all patient data will be included in the final locked database, we will remain blinded and will announce the comprehensive results of the full trial, including Stage II results, rather than proceeding with the original plan of announcing top line results for Stage I only.
So many patients chose to continue the treatment, that they couldn't have a intermediate data readout in november last year. SUPER BULLISH on those results. Don't forget that the primary endpoint are Patient Reported Outcomes (PRO's) GLTA
Only one's laughing at the end, will be the ones that timed this better than you did. As is often the case in biotech stocks. The results will be good, and you know that. That's the reason you invested in the first place.
You are just frustrated that even on good results, you won't be able to break-even. Which I completely understand, but trading emotionally like this, is not a good option
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025
Napo currently holds approximately 152 patents and approximately 43 patents pending.
https://jaguarhealth.gcs-web.com/news-releases/news-release-details/issuance-new-european-australian-patents-bolster-ip-protection
You will get it in less than 11 trading days.
This one is not for rookies like you
REGAINED COMPLIANCE: Press Release expected today. Source: https://listingcenter.nasdaq.com/noncompliantcompanylist.aspx
Going down?? Oh boy. Shorts borrowed ALL AVAILABLE shares , 35 000 !!! , at a cost to borrow rate of 253% !!!
And all you guys managed was a small 3% drop on a bad market day? It's pathetic, and shorts are losing EVERY DAY.
While BULLS are waiting FOR FREE.
Except Peter doesn't have the brains to explain us which shares they are going to sell. They didn't ask for extra shares on the shareholders meeting. And the only shares left are those of the 75 million MIXED share offering. Which can partly be used to issue more shares, but are much more warrants, or preferred shares; etcetera... To attract another kind of investors.
He is just too stupid to explain us. Don't mind this guy
Frustrated ... barely understandable English... Just don't pay attention to this guy.
Come on little boy, we allready crushed you last time, when we went up from 5 cents to 33 cents. Do you again want to get humiliated? You have NO power here, and NO credibility
I just don't know what people expect more from her? She put out so much press releases. Very transparent to the shareholders, but if you are keep being attacked by short sellers, you have to keep the company alive till you have something in hands what institutional buyers will back up... She finally is soo close to achieving that
Full data readout of a phase 3 trial, over 6 countries, 23 different therapies, after just 6/7 months (november -> july), knowing there was a statistical error in the application, is exactly fucking good work.
Only thing is that Lisa need to shut up about setting deadlines that (if we look back) were not realistic. And as you said, probably to save the PPS from worse
They have in hands the only drug ever that handles the cause of diarrhea, instead of creating constipation. They will have huge revenues in a few years time
I am glad you will be glad when you see the stockprice now!
Exactly what they want. Weak hands out. Good, so we can continue
I am going to mark this post LOL
8K filing. More royalities (1,5million) converted into shares (390 000 shares) for Iliad Research !!! Bullish !!
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee.
I know you are not smart, but is it too difficult to read a clinical trial for once? Study completion date: JUNE 2024.
Confirmed by the CEO by saying it is imminent
The chart won't tell you anything anymore after the biggest catalyst in the history of the company. Coming this month
Actually there is just 1 thing to say. The study completion date is June 2024
And today is the 3th trading day of June. Patience is key. All the rest is irrelevant
You are really a weak poster. The article clearly states that it are 'strategic splits' ... a regular split , or a reverse split. Second, the article obviously is stating in the first paragraph, that investors will be looking at these stocks in the coming days.
But hey, I really don't care if you want to stay negative. Time will tell right?
Would you 'consume' your biggest ever catalyst to try to reach compliance? With 290 million outstanding shares???
And reaching 1 dollar was even not the goal. The goal is well above 5 dollar, the treshold value for most institutional holdings. After phase 3 they need a partner, and institutional buyers.
Reverse split was a strategical split. As you can read here: https://www.openpr.com/news/3525996/nasdaq-stocks-soaring-to-the-top-with-strategic-splits-nvda
Why are you being so stupid? Why would they issue shares at these prices? when you have a huge catalyst???
That's the same as you would sell your shares rather at 4 dollars, instead of 40 dollars... exactly the same scenario. Wouldn't be smart is it?
Are you new to the stock market? We allready have the DEF14A file, we know exactly what they are going to ask at the shareholders meeting. And guess what, it's not more authorized shares. Just a few 100 thousand shares for the incentive program.
Meanwhile we still have the mixed offering of up to 75 million dollars that can be issued. Which they would logically do, if the shareprice is moving up dramatically because of phase 3 results.
I do agree with you. There was a lot of speculation (also from my side), which resulted in a lot of disappointment. But, if we line up the facts from what the company stated, than we are still perfect on schedule, because:
We became aware of the statistical error in the application, during the earnings call of April 1st. Around that time the clinical trial information was updated. The study completion date was set on JUNE 2024. On April 24th, there was the abstract title release of ASCO, with no mention of ONTARGET (so no presentation at ASCO).
May 14th the CEO stated that the results are imminent, which we can interpret as , we are perfectly on schedule for the release of the results in June 2024, as we stated back in April.
ASCO ended on the second trading day of June... Today will be the 3th trading day
Yeah 3 weeks ago.. mid may.. study completion date June 2024... So yeah, after 5 years... 3 weeks seems 'imminent'. So, I hope it will be this week
Study completion date is June 2024... We are at the first trading day of June. At the earnings call from April 1st, they perfectly explained what was the problem (statistical error),
So they brought in the biostatistic expert who did the phase 3 ADVENT trial for HIV, and who got Mytesi (crofelemer) FDA approved in the first place!
It was also around the earnings call that they updated the study completion date to June 2024.
Although, I really hoped that we would've got it before and during ASCO, there is still NO reason to say that they delay without a reason, or explanation.
Most 'investors' just are not up to date, or do not follow any earnings call ... Own fault. Keep yourself updated
Does not really come as a surprise for me, obviously the initial plan (Exhibitors allready sign in months in advance) was to present the ONTARGET results at ASCO. Like that was the plan allready in the summer of 2023...
But than we faced the statistical error that took time.
If data was indeed ready 2 weeks ago (hence imminent), it's obvious they couldn't prepare something for ASCO, especially no full booth. It takes time to get it through regulatory as well.
But, that's why I expect the data release on friday ! It will lure people to the NAPO booth, to talk about the new data release, because it will be big news at ASCO. Since ONTARGET has data for several types of cancer !
At least in my eyes that's the most opportune moment to release it... today or tomorrow
250 000 shares bought yesterday in after hours (Dark pool) , expect fireworks today !
But for how long ? You really think nobody is going to see that this is a drug with a multi billion dollar potential? At a market capacity of 20 million dollars? With allready products generating revenue?
This price action is a big manipulative joke. Eyes closed, and I will wait till the day comes
Exactly, I have never seen a stock being so manipulated on good news. But eventually it will all add oil to the fire. It will explode. Just patiently waiting till that day
But offcourse, since everyone is waiting for phase 3, it might have a minor effect on the stockprice , that's true! I just want to see the bigger picture...
General diarrhea in dogs + functional diarrhea in humans...
Crofelemer will become very big
Except that the prevalence of functional diarrhea = 4,7% in the total population...
I think a lot of people here don't see it, or don't want to see it. Functional diarrhea = + 6 months ... IMPOSSIBLE to take Imodium (loperamide) for so long. No treatments yet for functional diarrhea.
Crofelemer showing positive results... 4,7% of the total population ! This might be better news than cancer induced diarrhea